WHO said Saturday it has accepted the recommendation from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS.
WHO says the decision won’t affect possible trials on patients who aren’t hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward. The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with COVID-19. WHO said Saturday it has accepted the recommendation from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.
The agency adds that while there was no solid evidence of increased mortality for hospitalized patients given the drugs, there were some associated safety signals in the clinical laboratory findings of an associated trial.
Also read| Check Coronavirus latest updates here:
WHO says the decision won’t affect possible trials on patients who aren’t hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
